Nu Skin Enterprises, Inc. has released its financial results for the third quarter of 2026, revealing a decline in revenue and customer numbers. The company reported revenue of $311 million, marking a 14.6% decrease compared to the same period last year. Earnings per share (EPS) also fell, with a reported loss of $0.02, or $0.10 when excluding certain charges. This performance highlights ongoing challenges in the wholesale-drug industry.

Nu Skin Enterprises, Inc., incorporated in Delaware, operates primarily in the wholesale-drug sector, specifically categorized under SIC 5122, which includes drugs, proprietaries, and druggists' sundries. The company trades on the New York Stock Exchange under the ticker symbol NUS. Recent filings include an 8-K on November 5, 2026, detailing its financial results for the three- and nine-month periods ended September 30, 2026.

According to the filing, "On November 5, 2026, Nu Skin Enterprises, Inc. issued a press release announcing its financial results for the three- and nine-month periods ended September 30, 2026, and certain other information." The press release is attached as Exhibit 99.1 to the report.

The reported figures indicate that Nu Skin's customer base has declined by 18%, with a total of 609,469 customers. The number of paid affiliates also decreased by 10%, totaling 116,449. Additionally, the number of sales leaders dropped by 13%, reaching 26,995. These declines may impact the company's market position and could influence competitors in the wholesale-drug industry.

Looking ahead, the filing does not specify what actions Nu Skin will take in response to these results. However, the company remains focused on executing its strategic priorities, as stated by President and CEO Ryan Napierski. He noted, "Third quarter revenue came in within our guidance range as we continued executing on our strategic priorities amid a challenging operating environment." Nu Skin recently held its global convention in Japan, where it showcased new product offerings aimed at women's health.